Quince Therapeutics, Inc. - 10-Q Filing
Quince Therapeutics filed its quarterly report for the period ended March 31, 2026. The filing includes financial data and disclosures related to accrued liabilities, debt instruments including a European Investment Bank loan tranche B issued on October 20, 2023, equity incentive plans such as the Two Thousand And Nineteen Equity Incentive Plan and service-based stock options, research expenditures in Italy for Q1-Q4 of both 2025 and early 2026, and contingent consideration obligations. The report also details financial instruments including money market funds, warrants from a private placemen...
Tickers: $QNCX